学术报告－医学院

题目：Molecular basis of thrombosis and hemostasis: Lessons from intravital microscopy and immune thrombocytopenia models
血栓与止血的分子基础：关于活体显微镜检查和免疫性血小板减少症模型的研究
报告人：   Heyu Ni 博士
时  间：  2008年6月17日（星期二） 10：30
地  点：  医学院五楼学术报告厅
 
欢迎有兴趣的老师和同学参加!
主办单位：暨南大学医学院血液病研究所
          广东省抗癌协会血液肿瘤专业委员会


Heyu Ni 博士简介
多伦多大学生理学，病理生物学和医学实验室副教授。Ni博士目前主要从事血栓形成机制以及自身免疫系统疾病－血小板减少症发病机制等研究工作，并首次成功建立胎儿和新生儿同种免疫性血小板减少症动物模型。目前负责多项由Canadian Institutes of Health Research和Heart and Stroke Foundation of Canada等资助的相关科研项目，现已在国际科学期刊上发表研究论文数十篇。Ni博士现为美国血液学学会（ASH）、加拿大输血医学学会（CSTM)、美国血库协会（AABB)等国际知名学术协会会员，多种国际知名科学期刊如Blood, Journal of Biological Chemistry, Arteriosclerosis, Journal of Thrombosis and Haemostasis,  Cellular and Molecular Life Sciences, Journal of Leukocyte Biology, Current Medicinal Chemistry, Thrombosis and Haemostasis, European Journal of Hematology, Cardiovascular Pathology, Apoptosis和Platelets等杂志编委会成员。

 
Heyu Ni 博士简介
 
Associate Professor:  Department of Laboratory Medicine and Pathobiology,
                   Department of Medicine,
                   Department of Physiology, University of Toronto
Research Scientist:   Michael’s Hospital, University of Toronto
 
Educational Background：
B.Sc (M.D.) Department of Medicine, Anhui Medical University, Hefei, China.                                                                                                                                     
M.Sc.       Microbiology and Immunology, Department of Microbiology and Immunology, Anhui Medical University.
Ph.D.       Department of Immunology, University of Manitoba, Canada.
Professional Experience:
2001-present     Research Scientist   Michael’s Hospital, University of Toronto
2002- present    Visiting professor   Anhui Medical University
2003- present      Full faculty member
School of Graduate Studies, Institute of Medical Sciences, University of Toronto
2005-present      Faculty member
Heart and Stroke/Richard Lewar Centre of Excellence, University of Toronto            
2007- present      Associate Professor
Department of Laboratory Medicine and Pathobiology, Department of Medicine, Department of Physiology University of Toronto
Professional societies：
American Society of Hematology (ASH)
Canadian Society of Transfusion Medicine (CSTM)
American Association of Blood Banks (AABB)
International Society of Thrombosis and Haemostasis (ISTH)
Canadian Society of Atherosclerosis, Thrombosis and Vascular Biology (CSATV)
Journal Reviewer :
Blood, Journal of Biological Chemistry, Arteriosclerosis,
Thrombosis, and Vascular Biology, Journal of Thrombosis and Haemostasis, Cellular and Molecular Life Sciences, Journal of Leukocyte Biology, Current Medicinal Chemistry, Thrombosis and Haemostasis, European Journal of Hematology, Cardiovascular Pathology, Apoptosis, Platelets
Academic History:
Current Research Endeavors:
1. Vascular Biology: Thrombosis and Hemostasis
2. Autoimmune Diseases: autoimmune thrombocytopenia
3. Alloimmune Disease: maternal immune response to fetal platelet antigens
4. Adhesion Molecules and Cell Biology
 
Grants:
1. Heart and Stroke Foundation of Canada  (2008-2012)
Title: Novel Mechanisms of Platelet Aggregation: Unveiling new roles of non-classical integrin ligands in thrombosis and hemostasis.
2. Canadian Institutes of Health Research (CIHR, 2007-2011)
Title: Pathogenesis of fetal and neonatal alloimmune thrombocytopenia and IVIG therapy in novel murine models.
3. Canadian Blood Services intramural grant    (2007-2009)              
Title: Mechanism of Action of IVIG in a Murine Model of Fetal and Neonatal Alloimmune Thrombocytopenia: Role of neonatal Fc receptor (FcRn).
4. Bayer/Canadian Blood Services/ Hema-Quebec/Talecris partnership 2007-2009
Title: Mechanism of Action of IVIG in a Murine Model of Fetal and Neonatal Alloimmune Thrombocytopenia.
5.  CIHR /Canadian Blood Services Partnership Fund ( 2006-2009)
Title:Investigation of the pathogenesis of immune thrombocytopenia and efficacy and mechanism of action of intravenous IgG (IVIG).  
6. Heart and Stroke Foundation of Canada (co-applicant, 2008-2010)
Title: Developmental and Functional Characterization of Novel Regulators of Thrombopoiesis Identified by Mouse Mutagenesis.
7. Canadian Institutes of Health Research (co-applicant, 2006-2011)
Title: CIHR team grant in venous thromboembolism.
8. Heart and Stroke Foundation of Canada (co-applicant, 2007-2009)                                                
Title: Investigation of Lysophospatidic Acid (LPA) Generation and Platelet Function in Newly Developed lpdlr Phospholipase Deficient Mice.
 
Publications(within 5 years )
1. Heyu Ni*, et al.  Plasma fibronectin promotes thrombus growth in injured arterioles.  Proceedings of the National Academy of Sciences of USA (IF:10.2~ 10.7). 2003,100(5): 2415-2419
2. Heyu Ni*, et al. Control of Thrombus Embolization and Fibronectin Internalization by Integrin IL-3 Engagement of the Fibrinogen Chain. Blood (IF:10.13). 2003 ,102(10): 3609-3614
3. Adili Reheman, Peter Gross, Hong Yang, Pingguo Chen, David Allen, Valery Leytin, John Freedman, Heyu Ni*. Vitronectin Stabilizes Thrombi and Vessel Occlusion but Plays A Dual Role in Platelet Aggregation. Journal of Thrombosis and Haemostasis (IF: 5.3) 2005,3:875-883
4. Qingsheng Li, Jingsheng Wu, Zhimin Zhai, Yongsheng Han, Qing Li, Xiucai Xu, Heyu Ni*. Detection of plasma and platelet surface fibronectin in patients with acute myocardial infarction. Chinese Journal of Thrombosis and Hemostasis. 2005,11(2):76-78
5. Neelu Kaila, William S. Somers, Bert E. Thomas, Paresh Thakker, Kristin Janz,           Silvano DeBernardo, Steve Tam, William J. Moore, Ruiyang Yang, Wojciech Wrona, Patricia W. Bedard, Deidre Crommie, James C. Keith Jr., Desiree Tsao, Juan C. Alvarez, Heyu Ni*, et al. Quinic Acid Derivatives as Sialyl Lewisx -Mimicking Selectin Inhibitors: Design, Synthesis and Crystal Structure in Complex with E-Selectin. Journal of Medicinal Chemistry (IF:4.92 ~5.4). 2005, 48(13):4346-57
6. Yingchun Wang, Eric Vachon, Vera Cherepanov, Jun Li, Jinyi Zhang, Kan Saito, Theo Moraes, Tomoko Suzuki, Chung-Wai Chow, Joshua Kruger, Patrick Shannon, Nunzio Bottini, Huong Huynh, Heyu Ni*, et al. Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. Journal of Experimental Medicine (IF:14 ~16). 2005, 202(11):1587-97   
7. Rukhsana Aslam, Edwin R. Speck, Michael Kim, KW Annie Bang, Frederick P. Nestel, Heyu Ni*, et al.  Platelet toll-like receptor expression modulates lipopolysaccharide -induced thrombocytopenia and tumor necrosis factor-{alpha} production in vivo. Blood (IF:10.13). 2006,107 (2):637-641
8. Heyu Ni*, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: Response to intravenous IgG therapy. Blood (IF:10.13). 2006,107 (7): 2976-2983                                   
9. Valery Leytin, Sergiy Mykhaylov, Alison F Starkey, David J. Allen, Herbert Lau, Heyu Ni*, et al. IVIg Inhibits anti-GPIIb-induced platelet apoptosis in a murine model of ITP. British Journal of Haematology (IF:4.1). 2006 ,133(1):78-82.              
10. Michelle Webster, Ebrahim Sayeh, Min Crow, Pingguo Chen, Bernhard Nieswandt, John Freedman and Heyu Ni*. Relative efficacy of IVIG in ameliorating thrombocytopenia induced by anti-platelet GPIIbIIIa versus GPIb antibodies. Blood (IF:10.13). 2006 ,108(3):943-6                                                                                             
11. Xiucai Xu, Jingsheng Wu, Zhimin Zhai, Rongfu Zhou, Xuefeng Wang, Hongli Wang, Kaiyang Ding, Zimin Sun, Heyu Ni*. A novel fibrinogen Bβ chain frameshift mutation in a patient with severe congenital hypofibrinogenemia. Thrombosis and Haemostasis (IF:3.1), 2006,95: 931-935
12. Hong Yang, Adili Reheman, Pingguo Chen, Richard O. Hynes, John Freedman,   Denisa D. Wagner, Heyu Ni*. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. Journal of Thrombosis and Haemostasis (IF: 5.3). 2006, 4: 2230-2237
13.Tong Gui, Adili Reheman, William K. Funkhouser, Dwight A. Bellinger, John R Hagaman, Darrel W. Stafford, Paul E. Monahan and Heyu Ni*. In vivo response to vascular injury in the absence of factor IX: Examination in factor IX knockout mice. Thrombosis Research.  2007, 121(2): 225-234                                                                 
14. Zhimin Zhai, Jingsheng Wu, Xiucai Xu, Kaiyang Ding, Ran Ni, Wen Hu, Zimin Sun and Heyu Ni*. Fibrinogen Controls Human Platelet Fibronectin Internalization and Cell Surface Retention. Journal of Thrombosis and Haemostasis (impact factor =5.1). 2007 , 5: 1740-1746
15. Heyu Ni* Unveiling New Face of Fibronectin in Thrombosis and Haemostasis.  Editorial Commentary for the manuscript: Characterization of Fibronectin Assembly by Platelets Adherent to Adsorbed Laminin. Journal of Thrombosis and Haemostasis (IF: 5.3), 2006, 4 (5): 940-942
 
Patents:
1. Novel monoclonal antibodies against platelet GPIIIa (β3 integrin): potential anti-thrombotic drugs and research reagents for the study of thrombosis and hemostasis. IPF4  Identifying Number:HN-058. Application was filed on August 15, 2007 for US patent, and March 18, 2008 for European patent. We will move to next step of this application (in progress).   
2. Maternally administration of anti-FcRn antibodies as a therapy for Fetal and Neonatal Alloimmune Thrombocytopenia and other diseases caused by maternal pathogenic antibodies. IPF4 Identifying Number: H.N-064. Application submitted to Canadian Blood Services and has been reviewed by IPWG. We will move to next step of this application (in progress).   
3. Novel monoclonal antibodies against platelet GPIba: potential anti-thrombotic drugs and research reagents for study of thrombosis and hemostasis. IPF4 Identifying Number: H.N 065. Application submitted to Canadian Blood Services and has been reviewed by IPWG. We will move to next step of this application (in progress).   
 
作者：李晶